AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03603106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Part I: Placebo was administered intravenously with a flow rate ranging from 0.5 to 2 mL/s.~Part II: Placebo was administered intravenously with a flow rate of 2 mL/s.
Study NCT04183608 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Patients will all receive Adalimumab 160/80/40mg EOW until V1 (W14) followed by 40mg EOW until V2 (W26)
Study NCT04183608 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Calprotectin
Description: Fecal calprotectin dosing at home with IBDoc
Study NCT04183608 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: e-Monitoring
Description: e-Monitoring at Week 6, Week 10, Week 14, Week 18, Week 22, Week 26, Week 34, Week 38, Week 42 and Week 48~The patient must complete the first 2 questions of the Mayo score:~* Stool frequency~* The frequency of bleeding~He must also complete the information on his injections
Study NCT04183608 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapy Education
Description: Patient Education at W0, W2, W14, W26 and W38.
Study NCT02237638 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hVEGF26-104/RFASE
Description: Three intramuscular injections on days 0, 14 and 28, followed by an observational period of 6 weeks. If hererafter VEGF is not (or no longer) neutralized in serum and there is no sign of disease progression, another booster vaccination can be given. This booster can be repeated until disease progression, death or withdrawal from the study.
Study NCT05265897 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CAQ
Description: Informational document
Study NCT02403401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel (BAY98-7196)
Description: Levonorgestrel 40 µg/d intravaginal ring (treatment for 365 days, 28 days wearing period for each ring)
Study NCT02489669 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RenalGuard system™® (PLC Medical Systems, Inc. Franklin, MA, USA)
Description: Patients in the RenalGuard group will be treated by hydration with normal saline controlled by the RenalGuard system™® (PLC Medical Systems, Inc. Franklin, MA, USA). The RenalGuard system includes a) a closed loop fluid management system; b) a high volume fluid pump, c) a high accuracy dual weight measuring system; d) motion detection artifact reduction; e) a single use intravenous set and urine collection system that interfaces with a standard Foley catheter; f) real-time display of urine and replacement fluid volume; g) a timely alerts to drain the urine bag or to replace the hydration fluid bag; f) and safety features such as automatic air and occlusion detection.
Study NCT02599753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18-FDTBZ
Description: During this study, participants will receive a single i.v. administration of approximately 370MBq (10 mCi) 18F- DTBZ immediately prior to imaging. The dosage of DTBZ is 10 nmole. The effective dose in human body is about 5.6 mSV.~The proposed dose for this study is based on the investigators' phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG (Lin 2010).
Study NCT04650477 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fixation while forearm in extension-pronation position
Description: Fixation was performed after tenodesis in the extension-pronation position, which is the anatomically most suitable position of the biceps tendon.
Study NCT03904407 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lactobacillus Probiotic Capsule
Description: One over-the-counter, probiotic capsule taken by mouth once daily for 4 weeks. Each capsule contains 10 billion cells comprised of:~* Lactobacillus crispatus LbV 88~* Lactobacillus jensenii LbV 116~* Lactobacillus gasseri LbV 150N~* Lactobacillus rhamnosus LbV 96
Study NCT00901199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combo Chelation with Deferasirox (Exjade) and Deferoxamine (DFO)
Description: All subjects will be given Deferasirox 20-30 mg/kg for 7 days per week. All subject will be given Deferoxamine 50 mg/kg for 3-7 days per week. The number of days for Deferoxamine will be determined by liver iron concentration at baseline.
Study NCT04766008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Diabetic patients treated with metformin undergoing coronary angiography will not suspend metformin before and after PCI.
Study NCT03458468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: 1g Tranexamic acid prior to skin incision
Study NCT02353195 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Radiofrequency
Description: The equipment used, 35-mm diameter CAP and 30-mm diameter RES movable electrode was used on the affected site, and a planar electrode was used as a return electrode on the abdomen. The electricity was administered in the following manner: cream was applied to the site with the severest pain and its adjacent area, and the electrical output was increased by moving the movable electrode within the patient´s tolerance level, while monitoring the skin temperature tolerable to the patient.
Study NCT02353195 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiofrequency
Description: The equipment used, 35-mm diameter CAP and 30-mm diameter RES movable electrode was used on the affected site, and a planar electrode was used as a return electrode on the abdomen. The electricity was administered in the following manner: cream was applied to the site with the severest pain and its adjacent area, and the electrical output was increased by moving the movable electrode within the patient´s tolerance level, while monitoring the skin temperature tolerable to the patient.
Study NCT05977829 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Transvaginal ultrasound to carry out uterine surveillance
Study NCT05977829 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Hysteroscopy
Description: Outpatient hysteroscopy to carry out uterine surveillance
Study NCT03719989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine plus R-GDP
Description: azacitidine S.C 25 mg/m2 D1,2,3,4,5 rituximab I.V. 375 mg/m2 D8 gemcitabine I.V. 1,000 mg/m2, D8,15 dexamethasone I.V. or P.O. 40 mg D8,9,10,11 every 21 days, up to 6 cycles
Study NCT03122782 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical application Tranexamic acid
Description: Tranexamic acid (TXA) will be injected to distinction media during hysteroscopy in myomectomy
Study NCT03122782 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Normal saline)
Description: 5ml of normal saline will be added to every 500 ml of distension media
Study NCT01309776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tianeptine
Description: week1 : 25mg/day q.d., week2: 37.5mg/day b.i.d. (12.5mg 1T, 12.5mg 2T
Study NCT01309776 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: week1 : 5mg/day q.d., week2: 10mg/day q.d.
Study NCT03408184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar paravertebral group
Description: A mixture of 0.5 ml /kg bupivacaine (0.25%), and 0.5µg/Kg dexmedetomidine and Epinephrine 5 microgram/ ml.
Study NCT03408184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: The field block group
Description: A mixture of 0.5 ml /kg bupivacaine (0.25%), and 0.5µg/Kg dexmedetomidine and Epinephrine 5 microgram/ ml.
Study NCT01743742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E, Vitamin C
Study NCT01932502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clobazam (Onfi)
Description: Subject's clonazepam will be converted to the following Onfi doses per day:~Clonazepam 0.5mg converted to Onfi 10mg first week, then titrated up to 40mg per day.~Clonazepam 1.0-2.0mg converted to Onfi 20mg first week, then titrated up to 40mg per day.~Clonazepam 2-4mg converted to Onfi 20mg first week, then titrated up to 60mg per day.~Initial conversion will occur over two weeks followed by upward titration of up to 10mg increment per week toward the target dose. Down titration of up to 10mg will be allowed during the study.~The following will be the initial conversion schedule from clonazepam to Onfi:~Week 1: 50% reduction of clonazepam and starting dose of Onfi, replacing the reduced clonazepam dose with the conversion rate of clonazepam 0.5mg = Onfi 10mg.~Week 2: Discontinuing clonazepam and increasing the dosage of Onfi by two-fold. Week 3+: Titrate the dose of Onfi up to 40mg per day as tolerated
Study NCT01932502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Initial conversion and titration
Description: Initial conversion will occur over two weeks followed by upward titration of up to 10mg increment per week toward the target dose. Down titration of up to 10mg will be allowed during the study.
Study NCT01932502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conversion schedule - Week 1
Description: The following will be the initial conversion schedule from clonazepam to Onfi:~Week 1: 50% reduction of clonazepam and starting dose of Onfi, replacing the reduced clonazepam dose with the conversion rate of clonazepam 0.5mg=Onfi 10mg.
Study NCT01932502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conversion schedule - Week 2
Description: Week 2: Discontinuing clonazepam and increasing the dosage of Onfi by two-fold.
Study NCT01932502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conversion schedule - Week 3
Description: Week 3+: Titrate the dose of Onfi up to 40mg per day as tolerated.
Study NCT03458468 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Equivalent volume of saline prior to skin incision
Study NCT03808194 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conditional lottery incentive
Description: Participants in the lottery incentive arm must fulfill the following criteria to be entered into the lottery. Participants must visit the clinic by month 1, initiate ART by month 3 and achieve viral suppression by month 6. Participants in this arm will be eligible to win the lottery.
Study NCT03291392 — intervention group
Intervention type: GENETIC
Intervention: Gene expression or biomarkers exploration
Study NCT03147443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Individualized Decoction
Description: Applied in the Tested Drug Observation Period. It is the highly individualized treatment of traditional Chinese medicine,the modification of Bronchiectasis Stabilization Decoction(Radix Lithospermi 15 g, Rhizoma Fagopyri Cymosi 30 g, Radix Ophiopogonis 15 g, Poria cocos 15 g, Radix Astragali 20 g, Rhizoma Bletillae 10 g, Platycodon grandiflorum 10 g, and Semen Coicis 30 g) based on syndrome differentiation. For example,for patients with qi and yin deficiency syndrome, we added Radix Adenophorae, and Radix Rehmanniae Recens. Besides, the herbs in a prescription could be changed according to different symptoms of individual patients.
Study NCT03808194 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optimized ART linkage package
Description: Optimized ART linkage package
Study NCT03904407 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Matching Lactobacillus Probiotic Placebo Capsule
Description: Lactobacillus Probiotic placebo capsules identical in appearance taken by mouth once daily for 4 weeks
Study NCT03355586 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Electromagnetic navigation
Description: Electromagnetic navigation combined with use of radial EBUS probe and Rapid On Site Evaluation of Histology for diagnosis of peripheral pulmonary nodules.Controlled by cone beam CT.
Study NCT00724594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: NAC (100 mg/kg/dose) was given intravenously to mothers within 4 hours of diagnosis of chorioamnionitis, and every 6 hours until delivery. NAC was given to preterm (12.5 mg/kg/dose) and term infants (25 mg/kg/dose) every 12 hours for 5 doses after birth.
Study NCT04800211 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Test Product 1
Description: Subjects were instructed to completely replace their cigarettes with the Test Product 1 EVP (Nu Mark LLC, MarkTen® XL Bold CLASSIC)
Study NCT00724594 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Saline was given in the same volume, at the same timing as NAC infusions
Study NCT01087944 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Autoinjector
Description: Participants received Peginterferon alfa-2a 180 microgram subcutaneously once a week by autoinjector for 3 weeks.
Study NCT01087944 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pre-filled syringe
Description: Participants received Peginterferon alfa-2a 180 microgram subcutaneously once a week by pre-filled syringe for 3 weeks.
Study NCT04800211 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Test Product 2
Description: Subjects were instructed to completely replace their cigarettes with the Test Product 2 EVP (Nu Mark LLC, MarkTen® XL Bold MENTHOL)
Study NCT02195349 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK2831781
Description: GSK2831781 (100 milligram (mg)/mL) and its dilutions (Diluent - 0.9 percent saline solution containing 0.015 percent Polysorbate 80) as clear or opalescent, colourless, yellow to brown liquid solution administered by IV over approximately 2 hours.
Study NCT03147443 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Individualized Decoction
Description: Applied in the Tested Drug Observation Period. It is the highly individualized treatment of traditional Chinese medicine,the modification of Bronchiectasis Stabilization Decoction(Radix Lithospermi 15 g, Rhizoma Fagopyri Cymosi 30 g, Radix Ophiopogonis 15 g, Poria cocos 15 g, Radix Astragali 20 g, Rhizoma Bletillae 10 g, Platycodon grandiflorum 10 g, and Semen Coicis 30 g) based on syndrome differentiation. For example,for patients with qi and yin deficiency syndrome, we added Radix Adenophorae, and Radix Rehmanniae Recens. Besides, the herbs in a prescription could be changed according to different symptoms of individual patients.
Study NCT03147443 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Individualized Decoction
Description: Applied in the Tested Drug Observation Period. It is the highly individualized treatment of traditional Chinese medicine,the modification of Bronchiectasis Stabilization Decoction(Radix Lithospermi 15 g, Rhizoma Fagopyri Cymosi 30 g, Radix Ophiopogonis 15 g, Poria cocos 15 g, Radix Astragali 20 g, Rhizoma Bletillae 10 g, Platycodon grandiflorum 10 g, and Semen Coicis 30 g) based on syndrome differentiation. For example,for patients with qi and yin deficiency syndrome, we added Radix Adenophorae, and Radix Rehmanniae Recens. Besides, the herbs in a prescription could be changed according to different symptoms of individual patients.
Study NCT03147443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Applied in the placebo Observation Period. Placebo is made by dextrin, bitter agent, edible pigment etc and added 5% test drug. The test drug and control drug have no differences in dosage form, appearance, color, specification, label, and so forth.
Study NCT03147443 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Applied in the placebo Observation Period. Placebo is made by dextrin, bitter agent, edible pigment etc and added 5% test drug. The test drug and control drug have no differences in dosage form, appearance, color, specification, label, and so forth.
Study NCT03147443 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tested drug minus heat-clearing herbs
Description: It is the decoction of the Syndrome Differentiation Decoction(tested drug) minus heat-clearing herbs. For example, heat-clearing herbs such as Scutellaria baicalensis or Herba Violae will be removed from the Syndrome Differentiation Decoction.
Study NCT02180412 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panhematin
Description: Glucose loading
Study NCT02180412 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose
Description: Glucose is administered to both groups as routine care.
Study NCT02180412 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Glucose
Description: Glucose is administered to both groups as routine care.
Study NCT04078685 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard catheter ablation
Description: Radiofrequency catheter ablation using a standard ablation catheters: not equipped with contact-force sensing
Study NCT04078685 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contact Force-sensing-based catheter ablation
Description: Radiofrequency catheter ablation using a Contact-Force-sensing ablation catheter
Study NCT00973024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42160443 3 mg
Description: JNJ-42160443: type=exact number, unit=mg, number= 3, form=solution for injection, route=Subcutaneous use or Placebo: form=solution for injection, route=Subcutaneous injection. One inj of 3 mg of JNJ-42160443 or matching placebo every 4 wks for up to 104 wks.
Study NCT00973024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42160443 1 mg
Description: JNJ-42160443: type=exact number, unit=mg, number= 1, form=solution for injection, route=Subcutaneous use or Placebo: form=solution for injection, route=Subcutaneous injection. One inj of 1 mg of JNJ-42160443 or matching placebo every 4 wks for up to 104 wks.
Study NCT00973024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42160443 6 mg/3mg
Description: JNJ-42160443: type= exact number, unit= mg, number= 3 and 6, form=solution for injection, route= Subcutaneous use or Placebo: form= solution for injection, route= Subcutaneous injection. 1 inj of 6 mg of JNJ-42160443 on Day 1 followed by 1 inj of 3 mg or matching placebo every 4 wks for up to 104 wks.
Study NCT00973024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42160443 10 mg
Description: JNJ-42160443 10 mg: type=exact number, unit=mg, number= 10, form=solution for injection, route=Subcutaneous use or Placebo: form=solution for injection, route=Subcutaneous injection. One inj of 10 mg of JNJ-42160443 or matching placebo every 4 wks for up to 104 wks.
Study NCT00973024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Form= solution for injection, route= subcutaneous. Matching placebo given as a subcutaneous (SC) (under the skin) injection (inj) once every 4 weeks (wks).
Study NCT02195349 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Commercial saline solution administered by IV over approximately 2 hours
Study NCT01907477 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Samples taken at the clinical hematology unit
Study NCT02857478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 987519, SPF 50, Y51-002
Description: Sufficient amount to cover all exposed skin liberally two times - approximately 240 min.
Study NCT02857478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 987519, SPF 50, P04-147
Description: Sufficient amount to cover all exposed skin liberally two times - approximately 240 min.
Study NCT03327610 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VC-CMV20
Description: Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV). The inspiratory flow was set at 20Lpm and the tidal volume was increased in steps of 200mL until the peak airway pressure of 40cmH2O was achieved. After achieving the target pressure, this ventilatory regimen lasted 15 minutes. Positive end expiratory pressure and the inspired oxygen fraction were not modified.
Study NCT03327610 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VC-CMV50
Description: Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV). The inspiratory flow was set at 50Lpm and the tidal volume was increased in steps of 200mL until the peak airway pressure of 40cmH2O was achieved. After achieving the target pressure, this ventilatory regimen lasted 15 minutes. Positive end expiratory pressure and the inspired oxygen fraction were not modified.
Study NCT03327610 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PC-CMV1
Description: Application of a ventilator hyperinflation intervention with Pressure Control Continuous Mandatory Ventilation (PC-CMV1). The inspiratory time was set at 1 second and the pressure control was increased until a peak pressure of 40cmH2O was achieved. After achieving the target pressure, this ventilatory regimen lasted 15 minutes. Positive end expiratory pressure and the inspired oxygen fraction were not modified.
Study NCT03327610 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PC-CMV3
Description: Application of a ventilator hyperinflation intervention with Pressure Control Continuous Mandatory Ventilation (PC-CMV1). The inspiratory time was set at 3 seconds and the pressure control was increased until a peak pressure of 40cmH2O was achieved. After achieving the target pressure, this ventilatory regimen lasted 15 minutes. Positive end expiratory pressure and the inspired oxygen fraction were not modified.
Study NCT03327610 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PSV10
Description: Application of a ventilator hyperinflation intervention with Pressure Support Ventilation (PSV). The cycling off was set at 10% of peak inspiratory flow and the pressure support was increased until a peak pressure of 40cmH2O was achieved. After achieving the target pressure, this ventilatory regimen lasted 15 minutes. Positive end expiratory pressure and the inspired oxygen fraction were not modified.